Pharma Mar (Spain) Performance
| PHM Stock | EUR 75.50 0.10 0.13% |
Pharma Mar holds a performance score of 18 on a scale of zero to a hundred. The company holds a Beta of 0.11, which implies not very significant fluctuations relative to the market. As returns on the market increase, Pharma Mar's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pharma Mar is expected to be smaller as well. Use Pharma Mar treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to analyze future returns on Pharma Mar.
Risk-Adjusted Performance
18 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Pharma Mar SA are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady primary indicators, Pharma Mar exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 96.2 M | |
| Total Cashflows From Investing Activities | 18.5 M |
Pharma |
Pharma Mar Relative Risk vs. Return Landscape
If you would invest 4,020 in Pharma Mar SA on August 28, 2024 and sell it today you would earn a total of 3,530 from holding Pharma Mar SA or generate 87.81% return on investment over 90 days. Pharma Mar SA is generating 1.0609% of daily returns assuming 4.5105% volatility of returns over the 90 days investment horizon. Simply put, 40% of all stocks have less volatile historical return distribution than Pharma Mar, and 79% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Pharma Mar Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharma Mar's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pharma Mar SA, and traders can use it to determine the average amount a Pharma Mar's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2352
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PHM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.51 actual daily | 40 60% of assets are more volatile |
Expected Return
| 1.06 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.24 actual daily | 18 82% of assets perform better |
Based on monthly moving average Pharma Mar is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharma Mar by adding it to a well-diversified portfolio.
Pharma Mar Fundamentals Growth
Pharma Stock prices reflect investors' perceptions of the future prospects and financial health of Pharma Mar, and Pharma Mar fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharma Stock performance.
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 1.07 B | |||
| Shares Outstanding | 18.09 M | |||
| Price To Earning | (38.29) X | |||
| Price To Book | 5.69 X | |||
| Price To Sales | 5.17 X | |||
| Revenue | 229.83 M | |||
| EBITDA | 104.08 M | |||
| Cash And Equivalents | 42.72 M | |||
| Cash Per Share | 0.19 X | |||
| Total Debt | 33.39 M | |||
| Book Value Per Share | 9.88 X | |||
| Cash Flow From Operations | 25.68 M | |||
| Earnings Per Share | 4.64 X | |||
| Total Asset | 368.39 M | |||
About Pharma Mar Performance
By analyzing Pharma Mar's fundamental ratios, stakeholders can gain valuable insights into Pharma Mar's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharma Mar has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharma Mar has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain. PHARMA MAR operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 599 people.Things to note about Pharma Mar SA performance evaluation
Checking the ongoing alerts about Pharma Mar for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pharma Mar SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharma Mar SA appears to be risky and price may revert if volatility continues | |
| Pharma Mar SA has accumulated 33.39 M in total debt. Pharma Mar SA has a current ratio of 0.92, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Pharma Mar until it has trouble settling it off, either with new capital or with free cash flow. So, Pharma Mar's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pharma Mar SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pharma to invest in growth at high rates of return. When we think about Pharma Mar's use of debt, we should always consider it together with cash and equity. | |
| About 27.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pharma Mar's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharma Mar's stock is overvalued or undervalued compared to its peers.
- Examining Pharma Mar's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharma Mar's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharma Mar's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharma Mar's stock. These opinions can provide insight into Pharma Mar's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharma Stock analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |